Prevention of opportunistic infections in immune-compromised subjects

• US 9,217,133 B2
• Filed: 12/05/2008
• Issued: 12/22/2015
• Est. Priority Date: 12/17/2007
• Status: Active Grant

• Current Assignee: Societe des Produits Nestle SA (Nestle SA)
• Original Assignee: Nestec SA (Nestle SA)
• Inventors: Sprenger, Norbert
• Primary Examiner(s): Fox, Allison
• Assistant Examiner(s): Pyla, Yvonne
• Application Number:
  US12/808,053
• Publication Number:
  US 20100260720A1
• Time in Patent Office: 2,573 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 1/20 Bacteria; Culture media therefor

Abstract

This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium longum and a fucosylated oligosaccharide selected from the group comprising 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N-neohexaose. The invention further extends to the use of such a composition in the prevention of opportunistic infections in immune-compromised individuals.

Claims

1. A composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals, the composition comprising:

a probiotic selected from the group consisting of Bifidobacterium lactis CNCM I-3446 and Bifidobacterium longum ATCC BAA-999; and

a fucosylated oligosaccharide consisting of 2′

-fucosyllactose, wherein the composition is selected from the group consisting of an infant formula and a supplement, and wherein the 2′

-fucosyllactose is obtained by a process comprising a step selected from the group consisting of isolation from a natural source, chemical synthesis and biotechnological synthesis, and the 2′

-fucosyllactose is present in an amount of 0.1 to 3 g per 100 g of the composition.

2. The composition of claim 1, which is an infant formula.

3. The composition of claim 2, which comprises from 10e3 to 10e12 cfu of the probiotic/g infant formula.

4. The composition of claim 2, which comprises from 10e6 to 10e9 cfu of the probiotic/g infant formula.

5. The composition of claim 2, which comprises at least one prebiotic in an amount of from 0.3 to 10% by weight of the composition.

6. The composition of claim 1, which is a supplement and which comprises from 10e5 to 10e12 cfu of the probiotic per unit dose.

7. A composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals, the composition comprising:

a probiotic selected from the group consisting of Bifidobacterium lactis CNCM I-3446 and Bifidobacterium longum ATCC BAA-999; and

a fucosylated oligosaccharide consisting of 2′

-fucosyllactose, wherein the composition is selected from the group consisting of an infant formula and a supplement, and wherein the 2′

-fucosyllactose is obtained by a process comprising a step selected from the group consisting of isolation from a natural source, chemical synthesis and biotechnological synthesis.